Interpace Biosciences (IDXG) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-24249
Entity Registrant Name	Interpace Biosciences, Inc.
Entity Central Index Key	0001054102
Entity Tax Identification Number	22-2919486
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Morris Corporate Center 1
Entity Address, Address Line Two	Building C
Entity Address, Address Line Three	300 Interpace Parkway
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	855
Local Phone Number	776-6419
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,266,534

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 6,309	$ 2,672
Restricted cash		250
Accounts receivable	4,792	4,672
Other current assets	1,610	1,479
Current assets of discontinued operations	28	3,093
Total current assets	12,739	12,166
Property and equipment, net	428	317
Other intangible assets, net	1,179	2,132
Operating lease right of use assets	867	1,284
Other long-term assets	80	141
Long-term assets of discontinued operations		22,387
Total assets	15,293	38,427
Current liabilities:
Accounts payable	1,446	1,374
Accrued salary and bonus	1,631	2,689
Other accrued expenses	8,375	8,462
Line of credit - current	2,500
Current liabilities of discontinued operations	858	3,157
Total current liabilities	14,810	15,682
Contingent consideration	632	1,383
Operating lease liabilities, net of current portion	184	520
Line of credit		1,500
Note payable at fair value	9,988	7,942
Other long-term liabilities	4,736	4,577
Long-term liabilities of discontinued operations		2,705
Total liabilities	30,350	34,309
Commitments and contingencies (Note 9)
Redeemable preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 shares Series B issued and outstanding	46,536	46,536
Stockholders’ deficit:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,293,666 and 4,228,169 shares issued, respectively; 4,246,297 and 4,195,412 shares outstanding, respectively	404	403
Additional paid-in capital	187,390	186,106
Accumulated deficit	(247,453)	(227,059)
Treasury stock, at cost (47,369 and 32,757 shares, respectively)	(1,934)	(1,868)
Total stockholders’ deficit	(61,593)	(42,418)
Total liabilities and stockholders’ deficit	(31,243)	(8,109)
Total liabilities, preferred stock and stockholders’ deficit	$ 15,293	$ 38,427

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Temporary equity par value	$ 0.01	$ 0.01
Temporary equity shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	4,293,666	4,228,169
Common stock, shares outstanding	4,246,297	4,195,412
Treasury stock, shares	47,369	32,757
Series B Preferred Stock [Member]
Temporary equity shares issued	47,000	47,000
Temporary equity shares outstanding	47,000	47,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue, net	$ 8,189	$ 8,057	$ 23,506	$ 24,006
Cost of revenue	3,457	3,620	10,286	10,205
Gross profit	4,732	4,437	13,220	13,801
Operating expenses:
Sales and marketing	2,236	2,244	6,987	6,931
Research and development	191	322	626	1,178
General and administrative	2,767	2,566	8,636	7,389
Transition expense		236		897
Gain on DiamiR transaction				(235)
Acquisition related amortization expense	318	894	953	2,682
Change in fair value of contingent consideration			(311)	(57)
Total operating expenses	5,512	6,262	16,891	18,785
Operating loss from continuing operations	(780)	(1,825)	(3,671)	(4,984)
Interest accretion expense	(38)	(106)	(123)	(375)
Related party interest		(151)		(372)
Note payable interest	(230)		(620)
Other income (expense), net	(217)	49	(20)	(248)
Loss from continuing operations before tax	(1,265)	(2,033)	(4,434)	(5,979)
(Benefit) provision for income taxes	(11)	(714)	24	(684)
Loss from continuing operations	(1,254)	(1,319)	(4,458)	(5,295)
Loss from discontinued operations, net of tax	(12,954)	(2,242)	(15,936)	(5,919)
Net loss	$ (14,208)	$ (3,561)	$ (20,394)	$ (11,214)
Basic and diluted loss per share of common stock:
From continuing operations	$ (0.30)	$ (0.32)	$ (1.05)	$ (1.29)
From discontinued operations	(3.05)	(0.53)	(3.77)	(1.43)
Net loss per basic and diluted share of common stock	$ (3.35)	$ (0.85)	$ (4.82)	$ (2.72)
Weighted average number of common shares and common share equivalents outstanding:
Basic	4,242	4,165	4,227	4,119
Diluted	4,242	4,165	4,227	4,119

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning balance, shares at Dec. 31, 2020	4,075	20
Beginning balance at Dec. 31, 2020	$ 402	$ (1,773)	$ 184,404	$ (212,116)
Common stock issued,Shares	9
Common stock issued			108
Restricted stock issued, shares	12
Restricted stock issued, Value
Common stock issued through ESPP, shares	36
Common stock issued through ESPP
Treasury stock purchased, shares
Treasury stock purchased
Stock-based compensation expense			286
Net income (loss) attributable to parent				(4,207)
Ending balance, shares at Mar. 31, 2021	4,132	20
Ending balance at Mar. 31, 2021	$ 402	$ (1,773)	184,798	(216,323)
Beginning balance, shares at Dec. 31, 2020	4,075	20
Beginning balance at Dec. 31, 2020	$ 402	$ (1,773)	184,404	(212,116)
Ending balance, shares at Sep. 30, 2021	4,194	20
Ending balance at Sep. 30, 2021	$ 403	$ (1,773)	186,052	(223,330)
Beginning balance, shares at Mar. 31, 2021	4,132	20
Beginning balance at Mar. 31, 2021	$ 402	$ (1,773)	184,798	(216,323)
Common stock issued,Shares	10
Common stock issued
Treasury stock purchased, shares
Treasury stock purchased
Stock-based compensation expense			551
Net income (loss) attributable to parent				(3,446)
Ending balance, shares at Jun. 30, 2021	4,142	20
Ending balance at Jun. 30, 2021	$ 402	$ (1,773)	185,349	(219,769)
Common stock issued,Shares	13
Common stock issued			226
Common stock issued through ESPP, shares	39
Common stock issued through ESPP	$ 1
Treasury stock purchased, shares
Treasury stock purchased
Stock-based compensation expense			477
Net income (loss) attributable to parent				(3,561)
Ending balance, shares at Sep. 30, 2021	4,194	20
Ending balance at Sep. 30, 2021	$ 403	$ (1,773)	186,052	(223,330)
Beginning balance, shares at Dec. 31, 2021	4,228	33
Beginning balance at Dec. 31, 2021	$ 403	$ (1,868)	186,106	(227,059)
Common stock issued,Shares	35
Common stock issued	$ 1		58
Restricted stock issued, shares
Restricted stock issued, Value
Common stock issued through ESPP, shares	9
Common stock issued through ESPP
Treasury stock purchased, shares		13
Treasury stock purchased		$ (60)
Stock-based compensation expense			325
Net income (loss) attributable to parent				(2,247)
Ending balance, shares at Mar. 31, 2022	4,272	46
Ending balance at Mar. 31, 2022	$ 404	$ (1,928)	186,489	(229,306)
Beginning balance, shares at Dec. 31, 2021	4,228	33
Beginning balance at Dec. 31, 2021	$ 403	$ (1,868)	186,106	(227,059)
Ending balance, shares at Sep. 30, 2022	4,294	47
Ending balance at Sep. 30, 2022	$ 404	$ (1,934)	187,390	(247,453)
Beginning balance, shares at Mar. 31, 2022	4,272	46
Beginning balance at Mar. 31, 2022	$ 404	$ (1,928)	186,489	(229,306)
Common stock issued,Shares	5
Common stock issued
Treasury stock purchased, shares		1
Treasury stock purchased		$ (6)
Stock-based compensation expense			334
Net income (loss) attributable to parent				(3,939)
Ending balance, shares at Jun. 30, 2022	4,277	47
Ending balance at Jun. 30, 2022	$ 404	$ (1,934)	186,823	(233,245)
Common stock issued,Shares
Common stock issued			48
Common stock issued through ESPP, shares	17
Common stock issued through ESPP
Treasury stock purchased, shares
Treasury stock purchased
Stock-based compensation expense			519
Net income (loss) attributable to parent				(14,208)
Ending balance, shares at Sep. 30, 2022	4,294	47
Ending balance at Sep. 30, 2022	$ 404	$ (1,934)	$ 187,390	$ (247,453)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (20,394)	$ (11,214)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,206	4,350
Interest accretion expense	123	375
Bad debt recovery		(140)
Mark to market on warrants	(71)	137
Goodwill impairment	8,433
Intangible asset impairment	3,827
Amortization of deferred financing fees	45	110
Interest - note payable		372
Stock-based compensation	1,133	1,228
ESPP expense	46	86
Change in fair value of note payable	46
Change in fair value of contingent consideration	(311)	(57)
Gain on DiamiR transaction		(235)
Other gains and expenses, net		(2)
Changes in operating assets and liabilities:
Accounts receivable	107	1,788
Other current assets	(45)	(413)
Other long-term assets	(1)	(14)
Accounts payable	(447)	(2,084)
Accrued salaries and bonus	(1,312)	(433)
Accrued liabilities	(914)	(1,349)
Long-term liabilities	113	(6)
Net cash used in operating activities	(7,416)	(7,501)
Cash Flows From Investing Activity
Proceeds from sale of Interpace Pharma Solutions, net	7,431
Purchase of property and equipment	(126)	(192)
Sale of property and equipment		39
Net cash provided by (used in) investing activities	7,305	(153)
Cash Flows From Financing Activities
Issuance of common stock, net of expenses	106	335
Loan proceeds - related parties		7,500
Financing fees - related party		(123)
Proceeds from notes payable	2,000
Borrowings on line of credit	1,000
Net cash provided by financing activities	3,106	7,712
Net increase in cash, cash equivalents and restricted cash	2,995	58
Cash, cash equivalents and restricted cash from continuing operations– beginning	2,922	1,236
Cash, cash equivalents and restricted cash from discontinued operations– beginning	392	2,136
Cash, cash equivalents and restricted cash – beginning	3,314	3,372
Cash, cash equivalents and restricted cash from continuing operations– ending	6,309	2,916
Cash, cash equivalents and restricted cash from discontinued operations– ending		514
Cash, cash equivalents and restricted cash – ending	$ 6,309	$ 3,430

OVERVIEW

OVERVIEW	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OVERVIEW	1. OVERVIEW Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) is a company that provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. We develop and commercialize genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. COVID-19 pandemic There continues to be widespread impact from the COVID-19 pandemic. Beginning in the first quarter of 2021, there has been a trend in many parts of the world of increasing availability and administration of vaccines against COVID-19, as well as an easing of restrictions on social, business, travel and government activities and functions. On the other hand, infection rates and regulations continue to fluctuate in various regions and there are ongoing global impacts resulting from the pandemic, including challenges and increases in costs for logistics and supply chains. We have also previously been affected by temporary laboratory closures, employment and compensation adjustments and impediments to administrative activities. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location. In addition, we have experienced and are experiencing varying levels of inflation resulting in part from various supply chain disruptions, increased shipping and transportation costs, increased raw material and labor costs and other disruptions caused by the COVID-19 pandemic and general global economic conditions. The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future. We continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to our operating plans in reaction to developments that are beyond our control.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC), and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities & Exchange Commission (“SEC”) on March 31, 2022 and as amended on April 29, 2022. The Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions; and TVG, Inc., its Commercial Services business unit which was sold on December 22, 2015 and its Interpace Pharma Solutions business (“Pharma Solutions”) which was sold on August 31, 2022. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the nine-month period ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	3. GOING CONCERN The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. In October 2021, the Company entered into a $ 7.5 Revolving Line of Credit 8.0 2.0 Notes Payable In January 2022, the Company’s registration statement for a rights offering filed with the Securities and Exchange Commission (SEC) became effective; however, the rights offering was subsequently terminated later in January 2022 when the Company announced that the Centers for Medicare & Medicaid Services, or CMS, issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT ® ® ® ® ® 2,919 806 ® 806 ® ® 806 0.7 On August 31, 2022, the Company closed on the sale of its Pharma Solutions business for a total purchase price of $ 7,000,000 500,000 1,043,000 Discontinued Operations For the nine months ended September 30, 2022, we had an operating loss from continuing operations of $ 3.7 6.3 12.7 14.8 6.6 We will not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through targeted margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately. We continue to explore various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity. With the delisting of our common stock from Nasdaq in February 2021, our ability to raise additional capital on terms acceptable to us has been adversely impacted. There can be no assurance that we will be successful in obtaining such funding on terms acceptable to us. Our consolidated financial statements assume we will continue as a going concern. Our ability to continue as a going concern depends on having working capital for vendor payments, meeting short-term obligations on other accrued liabilities, and amongst other requirements, making interest payments on our debt obligations. Without positive operating margins and sufficient working capital and the ability to meet our debt obligations, our business will be jeopardized and we may not be able to continue in our current structure, if at all. Under these circumstances, we would likely have to consider other options, such as selling assets, raising additional debt or equity capital, cutting costs or otherwise reducing our cash requirements, or negotiating with our creditors to restructure our applicable obligations. With the proceeds received from the sale of the Pharma Solutions business, as well as the expected improvement in future operating cash flows associated with the disposition, as of the date of this filing, the Company anticipates that current cash and cash equivalents, available eligible borrowings on its Comerica Loan Agreement and forecasted cash receipts will be sufficient to meet its anticipated cash requirements through the next twelve months. Further, along with many laboratories, we may be affected by the Proposed Local Coverage Determination (“LCD”) DL39365, which was posted on June 9, 2022 and is currently under consideration by our local Medicare Administrative Contractor, Novitas Solutions, Inc. If finalized, this Proposed LCD, which governs “Genetic Testing for Oncology,” could impact the existing LCD for one of our molecular tests, PancraGEN ® ® The Company anticipates that current cash and cash equivalents and forecasted cash receipts would still be sufficient to meet its anticipated cash requirements through the next twelve months, from the date of this filing.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	4. DISCONTINUED OPERATIONS On August 31, 2022, the Company and Interpace Pharma Solutions, Inc. (the “Subsidiary”, and together with the Company as used in this Note 4, “Interpace”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Flagship Biosciences, Inc. (the “Purchaser”) pursuant to which the Purchaser agreed to (i) acquire substantially all of the assets of the Subsidiary used in Subsidiary’s business of complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics (the “Business”) and (ii) assume and pay certain liabilities related to the purchased assets as set forth in the Purchase Agreement (collectively, the “Transaction”). The Transaction closed on August 31, 2022. As consideration for the Transaction, under the Purchase Agreement, Interpace received a total purchase price of approximately $ 7.0 0.5 2.0 1.0 The Purchase Agreement includes a one-year commitment of Interpace not to compete with the Business, recruit or hire any former employees of the Subsidiary who accept employment with the Purchaser in connection with the Transaction, or divert or attempt to divert from Purchaser any business to be performed from any of the contracts or agreements with customers as set forth in the Purchase Agreement. The Purchase Agreement also contains customary representations and warranties, post-closing covenants and mutual indemnification obligations for, among other things, any inaccuracy or breach of any representation or warranty and any breach or non-fulfillment of any covenant. In connection with the Transaction, on August 31, 2022, Interpace and Purchaser entered into a Shared Services Agreement (the “Shared Services Agreement”) pursuant to which Interpace agreed to provide, or cause its affiliates to provide, to the Purchaser certain services set forth in the Shared Services Agreement on a transitional basis and subject to the terms and conditions set forth in the Shared Services Agreement (the “Services”). As consideration for the Services provided by Interpace, Purchaser will pay Interpace the amounts specified for each Service as set forth in the Shared Services Agreement. The Company’s obligations to provide the Services will terminate with respect to each Service as set forth in the Shared Services Agreement. The Purchaser is identified as a related party as an affiliate of Ampersand and an affiliate of BroadOak have each provided equity financing to the Purchaser, collectively own a majority of the Purchaser’s outstanding equity securities and are represented on its Board of Directors. The Company intends to use the remaining net proceeds to fund its future business activities and for general working capital purposes. As a result of the sale, the gain on sale and all operations from Interpace Pharma Solutions have been classified as discontinued operations for all periods presented. A reconciliation of the accounting for the Company’s Pharma Solutions business is as follows: SCHEDULE OF SALE OF BUSINESS Gain on Sale Purchase price $ 7,000 Earnout received 1,043 Working capital adjustment, net (656 ) Less: transaction costs (307 ) Total net consideration $ 7,080 Assets and liabilities disposed of, net (1) (7,080 ) Gain on sale $ - (1) includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $ 8.4 3.8 The components of liabilities classified as discontinued operations consist of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF COMPONENTS OF LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED OPERATIONS September 30, 2022 December 31, 2021 Accounts receivable, net $ - $ 1,486 Other 28 1,607 Current assets of discontinued operations 28 3,093 Property and equipment, net - 6,032 Other intangible assets, net - 5,155 Goodwill - 8,433 Other - 2,767 Long-term assets of discontinued operations - 22,387 Total assets $ 28 $ 25,480 Accounts payable - 1,320 Accrued salary and bonus 92 335 Other (1) 766 1,502 Current liabilities of discontinued operations 858 3,157 Operating lease liabilities, net of current portion - 2,634 Other - 71 Long-term liabilities of discontinued operations - 2,705 Total liabilities $ 858 $ 5,862 (1) Includes $ 766 The table below presents the significant components of its former Pharma Solutions business unit’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three-and nine-months ended September 30, 2022 and 2021. 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Revenue, net $ 1,267 $ 1,415 $ 5,678 $ 6,455 Loss from discontinued operations (13,012 ) (2,180 ) (15,888 ) (5,744 ) Gain (loss) on sale of Pharma Solutions - - - - Income tax (benefit) expense (58 ) 62 48 175 Loss from discontinued operations, net of tax $ (12,954 ) $ (2,242 ) $ (15,936 ) $ (5,919 ) The income tax benefit for the three months ended September 30, 2022 pertained to the reversal of a credit as a result of the Pharma Solutions sale. The income tax expense for both the three months ended September 30, 2021 and the nine months ended September 30, 2022 and 2021 pertained to interest accrued on uncertain tax position liabilities. Cash used from discontinued operations, operating activities, for the nine months ended September 30, 2022 was approximately $ 2.8 7.3 3.9 0.1

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	5. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates. Revenue Recognition We derive our revenues from the performance of proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. We regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. The Company recorded an NRV adjustment of $ 0.7 Going Concern, For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full. Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations. Accounts Receivable The Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases Other Current Assets Other current assets consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2022 December 31, 2021 (unaudited) Lab supply inventory $ 1,246 $ 825 Prepaid expenses 226 584 Other 138 70 Total other current assets $ 1,610 $ 1,479 Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Basic weighted average number of common shares 4,242 4,165 4,227 4,119 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,242 4,165 4,227 4,119 The Company’s Series B Convertible Preferred Stock, on an as converted basis into common stock of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Options 578 684 578 684 Restricted stock units (RSUs) 340 366 340 366 Warrants 54 1,405 54 1,405 Antidilutive securities excluded from computation of earnings per share 972 2,455 972 2,455

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	6. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill was attributable to the acquisition of our Pharma Solutions business in July 2019. The original carrying value of the intangible assets acquired was $ 15.6 8.3 7.3 zero SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of September 30, 2022 As of December 31, 2021 Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 CLIA Lab 2.3 609 609 Total $ 31,951 $ 31,951 Accumulated Amortization (30,772 ) (29,819 ) Net Carrying Value $ 1,179 $ 2,132 Amortization expense from continuing operations was approximately $ 0.3 0.9 1.0 2.7 SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2022 2023 2024 2025 2026 Total $ 318 $ 861 $ - $ - $ - $ 1,179 The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to September 30, 2022: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2021 $ 8,433 Impairment from sale of Pharma Solutions Business (8,433 ) Balance as of September 30, 2022 $ -

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	7. FAIR VALUE MEASUREMENTS Cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration, warrant liability and note payable. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below: SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of September 30, 2022 Fair Value Measurements Carrying Fair As of September 30, 2022 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 1,141 $ 1,141 $ - $ - $ 1,141 Other accrued expenses: Warrant liability (2) - - - - - Note payable: BroadOak loan 9,988 9,988 - - 9,988 $ 11,129 $ 11,129 $ - $ - $ 11,129 (1)(2) See Note 10, Accrued Expenses and Long-Term Liabilities (1) See Note 10, Accrued Expenses and Long-Term Liabilities (2) See Note 10, Accrued Expenses and Long-Term Liabilities As of December 31, 2021 Fair Value Measurements Carrying Fair As of December 31, 2021 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 1,871 $ 1,871 $ - $ - $ 1,871 Other accrued expenses: Warrant liability (2) 71 71 - - 71 Note payable: BroadOak loan 7,942 7,942 - - 7,942 $ 9,884 $ 9,884 $ - $ - $ 9,884 (1)(2) See Note 10, Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities In connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. In connection with the BroadOak loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted approach regarding the loan’s change in control feature. See Note 14, Notes Payable A roll forward of the carrying value of the Contingent Consideration Liability, 2017 Underwriters’ Warrants and BroadOak loans to September 30, 2022 is as follows: SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION December 31, 2021 Issued Reclassified Earned Accretion/Interest Accrued Adjustment to Fair Value/ Mark to Market September 30, 2022 (unaudited) Asuragen $ 1,871 $ - $ - $ (542 ) $ 123 $ (311 ) $ 1,141 Underwriters Warrants 71 - - - - (71 ) - BroadOak loans 7,942 - 2,000 - - 46 9,988 BroadOak Convertible Note - 2,000 (2,000 ) - - - - $ 9,884 $ 2,000 $ - $ (542 ) $ 123 $ (336 ) $ 11,129 Certain of the Company’s non-financial assets, such as other intangible assets, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
Leases
LEASES	8. LEASES Finance lease assets are included in fixed assets, net of accumulated depreciation. The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet September 30, 2022 (unaudited) Assets Financing lease assets Property and equipment, net $ - Operating lease assets Operating lease right of use assets 867 Total lease assets $ 867 Liabilities Current Financing lease liabilities Other accrued expenses $ - Operating lease liabilities Other accrued expenses 668 Total current lease liabilities $ 668 Noncurrent Financing lease liabilities Other long-term liabilities - Operating lease liabilities Operating lease liabilities, net of current portion 184 Total long-term lease liabilities 184 Total lease liabilities $ 852 The weighted average remaining lease term for the Company’s operating leases was 1.3 7.7 The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2022: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Operating Leases 2022 $ 208 2023 557 2024 125 Total minimum lease payments 890 Less: amount of lease payments representing effects of discounting 38 Present value of future minimum lease payments 852 Less: current obligations under leases 668 Long-term lease obligations $ 184 On October 31, 2022, the Company entered into a fourth lease amendment with its Pittsburgh laboratory landlord. See Note 20, Subsequent Events

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time. Due to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business. The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

ACCRUED EXPENSES AND LONG-TERM

ACCRUED EXPENSES AND LONG-TERM LIABILITIES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND LONG-TERM LIABILITIES	10. ACCRUED EXPENSES AND LONG-TERM LIABILITIES Other accrued expenses consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2022 December 31, 2021 (unaudited) Accrued royalties $ 4,675 $ 3,890 Contingent consideration 509 488 Operating lease liability 668 762 Interest payable 122 120 Warrant liability - 71 Accrued sales and marketing - diagnostics 47 47 Accrued lab costs - diagnostics 136 228 Accrued professional fees 699 932 Taxes payable 85 222 Unclaimed property 565 565 All others 869 1,137 Total other accrued expenses $ 8,375 $ 8,462 Long-term liabilities consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF LONG TERM LIABILITIES September 30, 2022 December 31, 2021 (unaudited) Uncertain tax positions $ 4,736 $ 4,577 Other - - Total other long-term liabilities $ 4,736 $ 4,577

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	11. STOCK-BASED COMPENSATION Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2022 and 2021. SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS September 30, 2022 September 30, 2021 (unaudited) Risk-free interest rate 1.76 % 0.78 % Expected life 6.0 6.0 Expected volatility 129.93 % 134.79 % Dividend yield - - During March 2021, the Company granted 312,500 6.00 152,500 5.00 0.5 0.4 1.1 1.1 SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30 September 30 2022 2021 2022 2021 (unaudited) (unaudited) Cost of revenue $ 19 $ 52 $ 67 $ 220 Sales and marketing 42 76 128 201 Research and development - 24 - 83 General and administrative * 440 276 915 635 Total stock compensation expense $ 501 $ 428 $ 1,110 $ 1,139 * Includes ESPP expense

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	12. INCOME TAXES Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on loss from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2022 and 2021: SCHEDULE OF EFFECTIVE INCOME TAX RATE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30 September 30 2022 2021 2022 2021 (unaudited) (unaudited) Provision (benefit) for income tax $ (11 ) $ (714 ) $ 24 $ (684 ) Effective income tax rate 0.9 % 35.1 % (0.5 )% 11.4 % Income tax benefit for the three months ended September 30, 2022 was primarily due to the reversal of certain credits as a result of the Pharma Solutions sale and income tax expense for the nine-month period ended September 30, 2022 was primarily due to minimum state and local taxes. The income tax benefit for both the three- and nine-month periods ended September 30, 2021 was due to the Company’s participation in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses (“NOLs”) and unused research and development credits to sell these benefits for at least 80 0.7

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	13. SEGMENT INFORMATION We operate under one

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	14. NOTES PAYABLE BroadOak Loan On October 29, 2021, the Company and its subsidiaries entered into the BroadOak Loan Agreement, providing for a term loan in the aggregate principal amount of $ 8,000,000 October 31, 2024 9 7,500,000 Revolving Line of Credit The Term Loan had an origination fee of 3 The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default. In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement. As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries. The Company concluded that the Note met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5 that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to shareholders’ equity. Accordingly, the Company elected the fair value option for the Note. BroadOak Convertible Note On May 5, 2022, the Company issued the Convertible Note to BroadOak, pursuant to which BroadOak funded a term loan in the aggregate principal amount of $ 2 The Convertible Note was to be converted into shares of common stock of the Company in connection with, and upon the consummation of, a private placement transaction pursuant to which the Company would issue common stock to certain investors, and such conversion would be subject to the same terms and conditions (including purchase price per share) applicable to the purchase of common stock of the Company by such investors. Since the private placement transaction was not consummated by August 5, 2022 (the “Maturity Date”), the Convertible Note was converted into an additional term loan advance under the Company’s existing BroadOak Loan Agreement on the Maturity Date and was thereafter subject to the terms of the definitive financing agreements for the BroadOak Loan Agreement until repaid in accordance with the terms thereof. The Convertible Debt bears interest at a fixed rate of interest equal to 9.0 In connection with the issuance of the Convertible Note, on May 5, 2022, the Company and its subsidiaries entered into a) a consent letter (the “Comerica Consent”) with Comerica, pursuant to which Comerica consented to the issuance of the Convertible Note, the incurrence of the Convertible Debt and the conversion of the Convertible Debt into common stock of the Company or an additional term loan advance under the BroadOak Loan Agreement in accordance with the terms of the Convertible Note, and b) a First Amendment to Loan and Security Agreement and Consent (the “BroadOak Amendment”) with BroadOak, pursuant to which, among other things, BroadOak consented to the issuance of the Convertible Note, the incurrence of the Convertible Debt and the conversion of the Convertible Debt into common stock of the Company or an additional term loan advance under the BroadOak Loan Agreement in accordance with the terms of the Convertible Note. The Convertible Debt is subordinated in right of payment to all of the indebtedness and obligations of the Company owing to Comerica under the Company’s existing senior secured credit facility with Comerica. In connection with the issuance of the Convertible Note, on May 5, 2022, the Company, BroadOak and Comerica entered into a First Amendment to Subordination and Intercreditor Agreement (the “Intercreditor Amendment”), pursuant to which, among other things, BroadOak agreed that the Convertible Debt is subordinated to all of the indebtedness and obligations of the Company owing to Comerica on the same terms and conditions applicable to the indebtedness and obligations of the Company under the BroadOak Loan Agreement. Related Party Secured Promissory Note On January 7, 2021, the Company entered into secured promissory notes in the amount of $ 3 2 4.5 3.0 On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. The Company used the proceeds of the BroadOak Term Loan discussed above to repay in full at their maturity all outstanding indebtedness under the promissory notes with Ampersand, dated January 7, 2021 and as last amended on September 29, 2021, in the amount of $ 4.5 3

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	15. SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Disclosures of Non Cash Activities (in thousands) SUPPLEMENTAL CASH FLOW INFORMATION 2022 2021 Nine Months Ended September 30, 2022 2021 Taxes accrued for treasury stock purchased $ 66 $ - Investment in DiamiR $ - $ 248 Purchase of property and equipment included in accounts payable $ 108 $ - Transaction costs from the sale of Pharma Solutions included in accounts payable $ 137 $ -

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
EQUITY	16. EQUITY Preferred Stock Issuance: Securities Purchase and Exchange Agreement On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $ 20.0 1,000 19,000 19.0 1,000 1.0 In addition, the Company agreed to exchange $ 27.0 0.01 270 100,000 27,000 6.00 In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. During October 2021, Ampersand and 1315 Capital provided consent to the Company to enter into the Comerica Loan Agreement and the BroadOak Term Loan. As of September 30, 2022 and December 31, 2021, there were 47,000

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2022
Warrants
WARRANTS	17. WARRANTS Warrants outstanding and warrant activity for the nine-months ended September 30, 2022 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Exercised Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 - (85,500 ) - RedPathWarrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 - (10,000 ) - Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 - - 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 (9 ) (870,205 ) - Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 - (320,000 ) - Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 - (65,434 ) - 1,975,934 1,404,648 (9 ) (1,351,139 ) 53,500 As of September 30, 2022, the weighted average exercise price of the outstanding warrants is $ 13.20 0.2

REVOLVING LINE OF CREDIT

REVOLVING LINE OF CREDIT	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
REVOLVING LINE OF CREDIT	18. REVOLVING LINE OF CREDIT On October 13, 2021, the Company and its subsidiaries entered into the Comerica Loan Agreement with Comerica, providing for a revolving credit facility of up to $ 7,500,000 The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $ 7,500,000 80 2,000,000 250,000 5,000,000 300,000 0.50 2.5 0.25 The Credit Facility matures on September 30, 2023, and is secured by a first priority lien on substantially all of the assets of the Company and its subsidiaries. As of September 30, 2022, the balance of the revolving line was $ 2.5 The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica Loan Agreement. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains financial covenants requiring specified minimum liquidity and minimum revenue thresholds, which the Company was in compliance with as of September 30, 2022, and also contains customary events of default. In April 2022, Comerica waived certain covenants specifically relating to the Company receiving financial statements with a going concern comment or qualification. In April 2022 and August 2022, Comerica waived certain covenants specifically relating to failure to maintain bank accounts outside of Comerica in an aggregate amount not to exceed $ 0.5 As a condition for Comerica to extend the Credit Facility to the Company and its subsidiaries, the Company’s existing creditors, Ampersand and 1315 Capital (the “Existing Creditors”), entered into that certain Subordination Agreement, dated as of October 13, 2021, pursuant to which each Existing Creditor agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to such Existing Creditor to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Subordination Agreement”). Each Existing Creditor further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Subordination Agreement provides that it is solely for the benefit of Comerica and each of the Existing Creditors and is not for the benefit of the Company or any of its subsidiaries.

RECENT ACCOUNTING STANDARDS

RECENT ACCOUNTING STANDARDS	9 Months Ended
	Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING STANDARDS	19. RECENT ACCOUNTING STANDARDS Accounting Pronouncements Pending Adoption In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU 2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect this will have any impact on its consolidated financial statements.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS Extension of Pittsburgh Lease On October 31, 2022, the Company entered into a fourth amendment (the “Amendment”) to its existing Pittsburgh laboratory lease (the “Lease”) for 20,000 550,000 250,000 200,000 8,333 4,632

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Accounting Estimates	Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.
Revenue Recognition	Revenue Recognition We derive our revenues from the performance of proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. We regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. The Company recorded an NRV adjustment of $ 0.7 Going Concern, For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.
Financing and Payment	Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
Costs to Obtain or Fulfill a Customer Contract	Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.
Accounts Receivable	Accounts Receivable The Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.
Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 8, Leases
Other Current Assets	Other Current Assets Other current assets consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2022 December 31, 2021 (unaudited) Lab supply inventory $ 1,246 $ 825 Prepaid expenses 226 584 Other 138 70 Total other current assets $ 1,610 $ 1,479
Long-Lived Assets, including Finite-Lived Intangible Assets	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Basic weighted average number of common shares 4,242 4,165 4,227 4,119 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,242 4,165 4,227 4,119 The Company’s Series B Convertible Preferred Stock, on an as converted basis into common stock of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Options 578 684 578 684 Restricted stock units (RSUs) 340 366 340 366 Warrants 54 1,405 54 1,405 Antidilutive securities excluded from computation of earnings per share 972 2,455 972 2,455

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF SALE OF BUSINESS	A reconciliation of the accounting for the Company’s Pharma Solutions business is as follows: SCHEDULE OF SALE OF BUSINESS Gain on Sale Purchase price $ 7,000 Earnout received 1,043 Working capital adjustment, net (656 ) Less: transaction costs (307 ) Total net consideration $ 7,080 Assets and liabilities disposed of, net (1) (7,080 ) Gain on sale $ - (1) includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $ 8.4 3.8
SCHEDULE OF COMPONENTS OF LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED OPERATIONS	The components of liabilities classified as discontinued operations consist of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF COMPONENTS OF LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED OPERATIONS September 30, 2022 December 31, 2021 Accounts receivable, net $ - $ 1,486 Other 28 1,607 Current assets of discontinued operations 28 3,093 Property and equipment, net - 6,032 Other intangible assets, net - 5,155 Goodwill - 8,433 Other - 2,767 Long-term assets of discontinued operations - 22,387 Total assets $ 28 $ 25,480 Accounts payable - 1,320 Accrued salary and bonus 92 335 Other (1) 766 1,502 Current liabilities of discontinued operations 858 3,157 Operating lease liabilities, net of current portion - 2,634 Other - 71 Long-term liabilities of discontinued operations - 2,705 Total liabilities $ 858 $ 5,862 (1) Includes $ 766 The table below presents the significant components of its former Pharma Solutions business unit’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three-and nine-months ended September 30, 2022 and 2021. 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Revenue, net $ 1,267 $ 1,415 $ 5,678 $ 6,455 Loss from discontinued operations (13,012 ) (2,180 ) (15,888 ) (5,744 ) Gain (loss) on sale of Pharma Solutions - - - - Income tax (benefit) expense (58 ) 62 48 175 Loss from discontinued operations, net of tax $ (12,954 ) $ (2,242 ) $ (15,936 ) $ (5,919 )

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF OTHER CURRENT ASSETS	Other current assets consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2022 December 31, 2021 (unaudited) Lab supply inventory $ 1,246 $ 825 Prepaid expenses 226 584 Other 138 70 Total other current assets $ 1,610 $ 1,479
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE	SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Basic weighted average number of common shares 4,242 4,165 4,227 4,119 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,242 4,165 4,227 4,119
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE 2022 2021 2022 2021 Three Months Nine Months Ended Ended September 30, Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Options 578 684 578 684 Restricted stock units (RSUs) 340 366 340 366 Warrants 54 1,405 54 1,405 Antidilutive securities excluded from computation of earnings per share 972 2,455 972 2,455

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE	SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of September 30, 2022 As of December 31, 2021 Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 CLIA Lab 2.3 609 609 Total $ 31,951 $ 31,951 Accumulated Amortization (30,772 ) (29,819 ) Net Carrying Value $ 1,179 $ 2,132
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE	SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2022 2023 2024 2025 2026 Total $ 318 $ 861 $ - $ - $ - $ 1,179
SCHEDULE OF GOODWILL CARRYING VALUE	The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to September 30, 2022: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2021 $ 8,433 Impairment from sale of Pharma Solutions Business (8,433 ) Balance as of September 30, 2022 $ -

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS	SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of September 30, 2022 Fair Value Measurements Carrying Fair As of September 30, 2022 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 1,141 $ 1,141 $ - $ - $ 1,141 Other accrued expenses: Warrant liability (2) - - - - - Note payable: BroadOak loan 9,988 9,988 - - 9,988 $ 11,129 $ 11,129 $ - $ - $ 11,129 (1)(2) See Note 10, Accrued Expenses and Long-Term Liabilities (1) See Note 10, Accrued Expenses and Long-Term Liabilities (2) See Note 10, Accrued Expenses and Long-Term Liabilities As of December 31, 2021 Fair Value Measurements Carrying Fair As of December 31, 2021 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 1,871 $ 1,871 $ - $ - $ 1,871 Other accrued expenses: Warrant liability (2) 71 71 - - 71 Note payable: BroadOak loan 7,942 7,942 - - 7,942 $ 9,884 $ 9,884 $ - $ - $ 9,884 (1)(2) See Note 10, Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities
SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION	A roll forward of the carrying value of the Contingent Consideration Liability, 2017 Underwriters’ Warrants and BroadOak loans to September 30, 2022 is as follows: SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION December 31, 2021 Issued Reclassified Earned Accretion/Interest Accrued Adjustment to Fair Value/ Mark to Market September 30, 2022 (unaudited) Asuragen $ 1,871 $ - $ - $ (542 ) $ 123 $ (311 ) $ 1,141 Underwriters Warrants 71 - - - - (71 ) - BroadOak loans 7,942 - 2,000 - - 46 9,988 BroadOak Convertible Note - 2,000 (2,000 ) - - - - $ 9,884 $ 2,000 $ - $ (542 ) $ 123 $ (336 ) $ 11,129

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
SCHEDULE OF FINANCING AND OPERATING LEASES	The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet September 30, 2022 (unaudited) Assets Financing lease assets Property and equipment, net $ - Operating lease assets Operating lease right of use assets 867 Total lease assets $ 867 Liabilities Current Financing lease liabilities Other accrued expenses $ - Operating lease liabilities Other accrued expenses 668 Total current lease liabilities $ 668 Noncurrent Financing lease liabilities Other long-term liabilities - Operating lease liabilities Operating lease liabilities, net of current portion 184 Total long-term lease liabilities 184 Total lease liabilities $ 852
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES	The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2022: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Operating Leases 2022 $ 208 2023 557 2024 125 Total minimum lease payments 890 Less: amount of lease payments representing effects of discounting 38 Present value of future minimum lease payments 852 Less: current obligations under leases 668 Long-term lease obligations $ 184

ACCRUED EXPENSES AND LONG-TER_2

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF OTHER ACCRUED EXPENSES	Other accrued expenses consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2022 December 31, 2021 (unaudited) Accrued royalties $ 4,675 $ 3,890 Contingent consideration 509 488 Operating lease liability 668 762 Interest payable 122 120 Warrant liability - 71 Accrued sales and marketing - diagnostics 47 47 Accrued lab costs - diagnostics 136 228 Accrued professional fees 699 932 Taxes payable 85 222 Unclaimed property 565 565 All others 869 1,137 Total other accrued expenses $ 8,375 $ 8,462
SCHEDULE OF LONG TERM LIABILITIES	Long-term liabilities consisted of the following as of September 30, 2022 and December 31, 2021: SCHEDULE OF LONG TERM LIABILITIES September 30, 2022 December 31, 2021 (unaudited) Uncertain tax positions $ 4,736 $ 4,577 Other - - Total other long-term liabilities $ 4,736 $ 4,577

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS	The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2022 and 2021. SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS September 30, 2022 September 30, 2021 (unaudited) Risk-free interest rate 1.76 % 0.78 % Expected life 6.0 6.0 Expected volatility 129.93 % 134.79 % Dividend yield - -
SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD	SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30 September 30 2022 2021 2022 2021 (unaudited) (unaudited) Cost of revenue $ 19 $ 52 $ 67 $ 220 Sales and marketing 42 76 128 201 Research and development - 24 - 83 General and administrative * 440 276 915 635 Total stock compensation expense $ 501 $ 428 $ 1,110 $ 1,139 * Includes ESPP expense

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE INCOME TAX RATE	SCHEDULE OF EFFECTIVE INCOME TAX RATE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30 September 30 2022 2021 2022 2021 (unaudited) (unaudited) Provision (benefit) for income tax $ (11 ) $ (714 ) $ 24 $ (684 ) Effective income tax rate 0.9 % 35.1 % (0.5 )% 11.4 %

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	Supplemental Disclosures of Non Cash Activities (in thousands) SUPPLEMENTAL CASH FLOW INFORMATION 2022 2021 Nine Months Ended September 30, 2022 2021 Taxes accrued for treasury stock purchased $ 66 $ - Investment in DiamiR $ - $ 248 Purchase of property and equipment included in accounts payable $ 108 $ - Transaction costs from the sale of Pharma Solutions included in accounts payable $ 137 $ -

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY	Warrants outstanding and warrant activity for the nine-months ended September 30, 2022 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Exercised Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 - (85,500 ) - RedPathWarrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 - (10,000 ) - Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 - - 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 (9 ) (870,205 ) - Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 - (320,000 ) - Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 - (65,434 ) - 1,975,934 1,404,648 (9 ) (1,351,139 ) 53,500

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)				3 Months Ended			9 Months Ended
	Aug. 31, 2022	Jun. 09, 2022	Jun. 08, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Nov. 04, 2022	May 05, 2022	Dec. 31, 2021	Oct. 31, 2021	Oct. 29, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Long-term line of credit											$ 1,500,000
Cost of product				3,457,000		$ 3,620,000	10,286,000	$ 10,205,000
NRV adjustment amount					$ 700,000
Sale of business units	$ 7,000,000
Escrow deposits related to property sales	500,000
Earnout payment	1,043,000
Operating loss				(780,000)		(1,825,000)	(3,671,000)	(4,984,000)
Cash, cash equivalents and restricted cash				6,309,000		$ 3,430,000	6,309,000	$ 3,430,000			3,314,000			$ 3,372,000
Total current assets				12,739,000			12,739,000				12,166,000
Current liabilities				14,810,000			14,810,000				$ 15,682,000
Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss							3,700,000
Cash, cash equivalents and restricted cash				6,300,000			6,300,000
Total current assets				12,700,000			12,700,000
Current liabilities				$ 14,800,000			$ 14,800,000
Cash									$ 6,600,000
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout payment	2,000,000
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout payment	$ 1,000,000
ThyGeNEXT [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of product					$ 806
ThyGeNEXT [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of product			$ 2,919
ThyGeNEXT [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of product		$ 806
Term Loan [Member] | Broad Oak [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term loan												$ 8,000,000	$ 8,000,000
Term Loan [Member] | Broad Oak [Member] | Convertible Debt [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term loan										$ 2,000,000
Comerica Bank [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Long-term line of credit												$ 7,500,000

SCHEDULE OF SALE OF BUSINESS (D

SCHEDULE OF SALE OF BUSINESS (Details) $ in Thousands	Aug. 31, 2022 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Purchase price	$ 7,000
Earnout received	1,043
Working capital adjustment, net	(656)
Less: transaction costs	(307)
Total net consideration	7,080
Assets and liabilities disposed of, net	(7,080)	[1]
Gain on sale
[1]includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $ 8.4 3.8

SCHEDULE OF SALE OF BUSINESS _2

SCHEDULE OF SALE OF BUSINESS (Details) (Parenthetical) - USD ($) $ in Thousands	Aug. 31, 2022	Sep. 30, 2022
Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilites related to business unit		$ 766
Goodwill [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation write down	$ 8,400
Finite-Lived Intangible Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation write down	$ 3,800

SCHEDULE OF COMPONENTS OF LIABI

SCHEDULE OF COMPONENTS OF LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operations		$ 28		$ 28		$ 3,093
Current liabilities of discontinued operations		858		858		3,157
Income tax (benefit) expense		(11)	$ (714)	24	$ (684)
Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net						1,486
Other		28		28		1,607
Current assets of discontinued operations		28		28		3,093
Property and equipment, net						6,032
Other intangible assets, net						5,155
Goodwill						8,433
Other						2,767
Long-term assets of discontinued operations						22,387
Total assets		28		28		25,480
Accounts payable						1,320
Accrued salary and bonus		92		92		335
Other	[1]	766		766		1,502
Current liabilities of discontinued operations		858		858		3,157
Operating lease liabilities, net of current portion						2,634
Other						71
Long-term liabilities of discontinued operations						2,705
Total liabilities		858		858		$ 5,862
Revenue, net		1,267	1,415	5,678	6,455
Loss from discontinued operations		(13,012)	(2,180)	(15,888)	(5,744)
Gain (loss) on sale of Pharma Solutions
Income tax (benefit) expense		(58)	62	48	175
Loss from discontinued operations, net of tax		$ (12,954)	$ (2,242)	$ (15,936)	$ (5,919)
[1]Includes $ 766

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)		9 Months Ended
	Aug. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Sale of business units	$ 7,000,000
Escrow deposits related to property sales	500,000
Earnout payment	1,043,000
Cash used in operating activities discontinued operations		$ 2,800,000	$ 3,900,000
Cash used in investing activities discontinued operations		$ 7,300,000	$ 100,000
Maximum [Member]
Earnout payment	2,000,000
Minimum [Member]
Earnout payment	$ 1,000,000

SCHEDULE OF OTHER CURRENT ASSET

SCHEDULE OF OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Lab supply inventory	$ 1,246	$ 825
Prepaid expenses	226	584
Other	138	70
Total other current assets	$ 1,610	$ 1,479

SCHEDULE OF BASIC AND DILUTED N

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Basic weighted average number of common shares	4,242	4,165	4,227	4,119
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	4,242	4,165	4,227	4,119

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	972	2,455	972	2,455
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	578	684	578	684
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	340	366	340	366
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	54	1,405	54	1,405

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Net realizable value adjustment	$ 0.7
Common stock, par value		$ 0.01	$ 0.01
Series B Preferred Stock [Member]
Number of preferred stocks on converted basis		7,833,334

SCHEDULE OF IDENTIFIABLE INTANG

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total	$ 31,951	$ 31,951
Accumulated Amortization	(30,772)	(29,819)
Net Carrying Value	1,179	2,132
CLIA Lab [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 609	609
Finite lived intangible asset, useful life	2 years 3 months 18 days
Asuragen Acquisition [Member] | Thyroid [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 8,519	8,519
Finite lived intangible asset, useful life	9 years
Red Path Acquisition [Member] | Pancreas Test [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 16,141	16,141
Finite lived intangible asset, useful life	7 years
Red Path Acquisition [Member] | Barretts Test [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 6,682	$ 6,682
Finite lived intangible asset, useful life	9 years

SCHEDULE OF FUTURE ESTIMATED AM

SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 318
2023	861
2024
2025
2026
Total	$ 1,179	$ 2,132

SCHEDULE OF GOODWILL CARRYING V

SCHEDULE OF GOODWILL CARRYING VALUE (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 8,433
Adjustments	(8,433)
Goodwill, ending balance

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Goodwill							$ 8,433
Amortization expense		$ 300	$ 900	$ 1,000	$ 2,700
BioPharma Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Intangible assets	$ 15,600
Goodwill	8,300					$ 0
Identifiable intangible assets	$ 7,300

SCHEDULE OF FINANCIAL INSTRUMEN

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details) - USD ($) $ in Thousands	Sep. 30, 2022		Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]	$ 71	[2]
Notes payable	9,988		7,942
Fair value of liabilities	11,129		9,884
Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]	71	[2]
Fair value of liabilities	11,129		9,884
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]		[2]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]		[2]
Fair value of liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]	71	[2]
Fair value of liabilities	11,129		9,884
Asuragen [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,141	[3]	1,871	[4]
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,141	[3]	1,871	[4]
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		[3]		[4]
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		[3]		[4]
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,141	[3]	1,871	[4]
BroadOak Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable	9,988		7,942
BroadOak Loan [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable	9,988		7,942
BroadOak Loan [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable
BroadOak Loan [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable
BroadOak Loan [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable	$ 9,988		$ 7,942
[1]See Note 10, Accrued Expenses and Long-Term Liabilities Accrued Expenses and Long-Term Liabilities Accrued Expenses and Long-Term Liabilities Accrued Expenses and Long-Term Liabilities

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Beginning balance	$ 9,884
Issued	2,000
Reclassified
Payments	(542)
Accretion/interest accrued	123
Adjustment to fair value/mark to market	(336)
Ending balance	11,129
Reclassified
BroadOak Loan [Member]
Beginning balance	7,942
Issued
Reclassified	2,000
Payments
Accretion/interest accrued
Adjustment to fair value/mark to market	46
Ending balance	9,988
Reclassified	(2,000)
BroadOak Convertible Note [Member]
Beginning balance
Issued	2,000
Reclassified	2,000
Payments
Accretion/interest accrued
Adjustment to fair value/mark to market
Ending balance
Reclassified	(2,000)
Underwriter Warrants [Member]
Beginning balance	71
Issued
Reclassified
Payments
Accretion/interest accrued
Adjustment to fair value/mark to market	(71)
Ending balance
Reclassified
Asuragen [Member]
Beginning balance	1,871
Issued
Reclassified
Payments	(542)
Accretion/interest accrued	123
Adjustment to fair value/mark to market	(311)
Ending balance	1,141
Reclassified

SCHEDULE OF FINANCING AND OPERA

SCHEDULE OF FINANCING AND OPERATING LEASES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
Finance lease assets
Operating lease assets	867	$ 1,284
Total lease assets	867
Finance lease, liability, current
Operating lease, liability, current	668	762
Total current lease liabilities	668
Finance lease, liability, noncurrent
Operating lease, liability, noncurrent	184	$ 520
Total long-term lease liabilities	184
Total lease liabilities	$ 852

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
2022	$ 208
2023	557
2024	125
Total minimum lease payments	890
Less: amount of lease payments representing effects of discounting	38
Present value of future minimum lease payments	852
Less: current obligations under leases	668	$ 762
Long-term lease obligations	$ 184	$ 520

LEASES (Details Narrative)

LEASES (Details Narrative)	Sep. 30, 2022
Leases
Operating lease, weighted average remaining lease term	1 year 3 months 18 days
Operating lease, weighted average discount rate, percent	7.70%

SCHEDULE OF OTHER ACCRUED EXPEN

SCHEDULE OF OTHER ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued royalties	$ 4,675	$ 3,890
Contingent consideration	509	488
Operating lease liability	668	762
Interest payable	122	120
Warrant liability		71
Accrued sales and marketing - diagnostics	47	47
Accrued lab costs - diagnostics	136	228
Accrued professional fees	699	932
Taxes payable	85	222
Unclaimed property	565	565
All others	869	1,137
Total other accrued expenses	$ 8,375	$ 8,462

SCHEDULE OF LONG TERM LIABILITI

SCHEDULE OF LONG TERM LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Uncertain tax positions	$ 4,736	$ 4,577
Other
Total other long-term liabilities	$ 4,736	$ 4,577

SCHEDULE OF STOCK OPTIONS, VALU

SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	1.76%	0.78%
Expected life	6 years	6 years
Expected volatility	129.93%	134.79%
Dividend yield

SCHEDULE OF SHARE-BASED COMPENS

SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		$ 501	$ 428	$ 1,110	$ 1,139
Cost of Sales [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		19	52	67	220
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		42	76	128	201
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense			24		83
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	[1]	$ 440	$ 276	$ 915	$ 635
[1]Includes ESPP expense

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement by share based payment award, options, grants in period, gross			312,500
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value			$ 6
Stock issued during period, shares, restricted stock award, gross			152,500
Shares issued, price per share			$ 5
Share based payment arrangement, expense	$ 0.5	$ 0.4		$ 1.1	$ 1.1
Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description				stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Provision (benefit) for income tax	$ (11)	$ (714)	$ 24	$ (684)
Effective income tax rate	0.90%	35.10%	(0.50%)	11.40%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Income Tax Disclosure [Abstract]
Income tax benefit percentage related research and development	80%
Operating loss carryforwards	$ 0.7

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Sep. 30, 2022 Integer
Segment Reporting [Abstract]
Number of segments	1

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Oct. 29, 2021	Sep. 29, 2021	Sep. 30, 2022	May 05, 2022	Dec. 31, 2021	Oct. 31, 2021	Oct. 13, 2021	May 10, 2021	Jan. 07, 2021
Line of Credit Facility [Line Items]
Revolving credit facility					$ 1,500,000
Comerica Bank [Member]
Line of Credit Facility [Line Items]
Revolving credit facility						$ 7,500,000
Loan and Security Agreement [Member]
Line of Credit Facility [Line Items]
Revolving credit facility							$ 7,500,000
Loan and Security Agreement [Member] | Comerica Bank [Member]
Line of Credit Facility [Line Items]
Revolving credit facility	$ 7,500,000
Debt instrument interest, description	The Term Loan had an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date.
1315 Capital Note [Member] | Security Agreement [Member]
Line of Credit Facility [Line Items]
Promissory note								$ 3,000,000
Term Loan [Member] | Broad Oak [Member]
Line of Credit Facility [Line Items]
Aggregate principal amount	$ 8,000,000					$ 8,000,000
Term Loan [Member] | Broad Oak [Member] | Convertible Debt [Member]
Line of Credit Facility [Line Items]
Aggregate principal amount				$ 2,000,000
Debt interest percentage				9%
Term Loan [Member] | Ampersand 2018 [Member]
Line of Credit Facility [Line Items]
Maturity date	Oct. 31, 2024
Debt interest percentage	9%
Percentage of debt origination fee	3%
Term Loan [Member] | Ampersand [Member]
Line of Credit Facility [Line Items]
Repayment of notes		$ 4,500,000
Term Loan [Member] | 1315 Capital [Member]
Line of Credit Facility [Line Items]
Repayment of notes		$ 3,000,000
Ampersand Notes [Member]
Line of Credit Facility [Line Items]
Promissory note									$ 3,000,000
1315 Capital Note [Member] | Security Agreement [Member]
Line of Credit Facility [Line Items]
Promissory note									$ 2,000,000
Ampersand Note [Member] | Security Agreement [Member]
Line of Credit Facility [Line Items]
Promissory note								$ 4,500,000

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Taxes accrued for treasury stock purchased	$ 66
Investment in DiamiR		248
Purchase of property and equipment included in accounts payable	$ 108

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jan. 10, 2020	Sep. 30, 2022	Dec. 31, 2021
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued		27,000
Preferred stock adjusted conversion		$ 6
Temporary equity, shares issued		47,000	47,000
Temporary equity, shares outstanding		47,000	47,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued		270
Value of preferred stock exchanged		$ 27
Preferred stock par/stated value		$ 0.01
Preferred shares stated value		$ 100,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock aggregate value	$ 20
Issuance price of preferred stock	$ 1,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member]
Class of Stock [Line Items]
Preferred stock aggregate value	$ 19
Aggregate of shares issued	19,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand 2018 Limited Partnership [Member]
Class of Stock [Line Items]
Preferred stock aggregate value	$ 1
Aggregate of shares issued	1,000

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY (Details) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Warrants issued	1,975,934
Warrants	53,500	1,404,648
Warrants exercised	(9)
Warrants cancelled/expired	(1,351,139)
Warrants One [Member]
Warrant Description	Private Placement Warrants, issued January 25, 2017
Classification	Equity
Exercise price	$ 46.90
Expiration date	June 2022
Warrants issued	85,500
Warrants		85,500
Warrants exercised
Warrants cancelled/expired	(85,500)
Warrants Two [Member]
Warrant Description	RedPathWarrants, issued March 22, 2017
Classification	Equity
Exercise price	$ 46.90
Expiration date	September 2022
Warrants issued	10,000
Warrants		10,000
Warrants exercised
Warrants cancelled/expired	(10,000)
Warrants Three [Member]
Warrant Description	Underwriters Warrants, issued June 21, 2017
Classification	Liability
Exercise price	$ 13.20
Expiration date	December 2022
Warrants issued	57,500
Warrants	53,500	53,500
Warrants exercised
Warrants cancelled/expired
Warrants Four [Member]
Warrant Description	Base & Overallotment Warrants, issued June 21, 2017
Classification	Equity
Exercise price	$ 12.50
Expiration date	June 2022
Warrants issued	1,437,500
Warrants		870,214
Warrants exercised	(9)
Warrants cancelled/expired	(870,205)
Warrants Five [Member]
Warrant Description	Warrants issued October 12, 2017
Classification	Equity
Exercise price	$ 18
Expiration date	April 2022
Warrants issued	320,000
Warrants		320,000
Warrants exercised
Warrants cancelled/expired	(320,000)
Warrants Six [Member]
Warrant Description	Underwriters Warrants, issued January 25, 2019
Classification	Equity
Exercise price	$ 9.40
Expiration date	January 2022
Warrants issued	65,434
Warrants		65,434
Warrants exercised
Warrants cancelled/expired	(65,434)

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares
Weighted average exercise price	$ 13.20
Weighted average remaining contractual life	2 months 12 days

REVOLVING LINE OF CREDIT (Detai

REVOLVING LINE OF CREDIT (Details Narrative) - USD ($)	Oct. 13, 2021	Sep. 30, 2022	Aug. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Line of credit					$ 1,500,000
Transition period convenants			$ 500,000
Loan and Security Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit	$ 7,500,000
Percentage of accounts receivable	80%
Line of credit reductions				$ 250,000
Line of credit	$ 5,000,000
Revolving line option credit card services borrowing limit	$ 300,000
Interest rate	0.50%
Percentage of line of credit unused facility fee	0.25%
Loan and Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Interest rate	2.50%
Loan and Security Agreement [Member] | Accounts Receivable [Member]
Line of Credit Facility [Line Items]
Line of credit	$ 2,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit		$ 2,500,000
Comerica Loan Agreement [Member] | Comerica Bank [Member] | Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit	$ 7,500,000,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	Oct. 31, 2022 USD ($) ft²
Subsequent Event [Line Items]
Area of land, lease | ft²	20,000
Rent payment	$ 550,000
Rennovations cost	250,000
Improvement cost	200,000
Lease monthly installments	$ 8,333
Additional area of land, lease | ft²	4,632